Brawn Biotech share news and announcements
BSE: 530207Pharmaceuticals & BiotechnologySmall Cap
Share price at the BSE close on 21 Oct 2026. Previous close ₹25.40.
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies.
- ₹7.62 Cr4,925th largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. The filing of 13 Aug 2026
- 8.9
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. The filing of 12 Jun 2026
- 1.8
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- Nonein the last 12 months
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it. The filing of 13 Aug 2026
- 22.3%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet. The filing of 13 Aug 2026
- −12.6%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026. The filing of 12 Jun 2026
- 0.00
- Volume, BSEVolume. Shares traded on the last trading day.
- 4
Brawn Biotech share news and announcements
399 announcements, routine notices left out, newest first. Page 2 of 8.
Feb 2025
4 Feb · Board meeting
Meeting on 12 Feb 2025: quarterly results
Nov 2024
22 Nov · Disclosure Of Non-Applicability For Filing Of Related Party Transaction
7 Nov · Board meeting
Meeting on 14 Nov 2024: quarterly results
Sep 2024
30 Sep · Intimation Of Regularization Of Independent Directors
Aug 2024
27 Aug · Management
14 Aug · Result For The Quarter Ended 30/06/2024
14 Aug · Board meeting
8 Aug · Board meeting
Meeting on 14 Aug 2024: quarterly results
Jun 2024
14 Jun · Declaration Under Regulation 33(3)(D) Of SEBI (Listing Obligations And Disclosures Requirements) Regulations, 2015
May 2024
29 May · Board meeting
23 May · Board meeting
Meeting on 29 May 2024: audited results
Apr 2024
11 Apr · Compliance Certificate Under Regulation 7(3) Of SEBI (LODR) Regulations, 2015.
9 Apr · Compliance Certificate Under Regulation 40(9) Of LODR For The Financial Year Ended On 31St March 2024
Feb 2024
14 Feb · Board meeting
8 Feb · Board meeting
Meeting on 14 Feb 2024: quarterly results
Nov 2023
16 Nov · Non Applicability For Filing Of Related Party Disclosures
3 Nov · Board meeting
Meeting on 10 Nov 2023: quarterly results
Sep 2023
Aug 2023
2 Aug · Board meeting
Meeting on 9 Aug 2023: quarterly results1 Aug · Intimation To The Shareholders For Transfer Of Equity Shares Of The Company To Investor Education And Protection Fund (IEPF)
Jun 2023
6 Jun · Non Applicability To File Related Party Transaction U/R 23(9)
May 2023
29 May · Result For The Quarter Ended 31/03/2023
23 May · Board meeting
Meeting on 29 May 2023: audited results